cancer treatment $6m mkt cap looks cheap

Capped at $6m with about $1.5m in the bank

Has some exciting Cancer treatment drugs under license

"The Company is confident that it can build on the experience with its Co-X-Gene™ technology and generate further licensing opportunities such as that executed with
major French biotechnology company Transgene for access to Virax’s Co-X-Gene™ technology for use in two of Transgene’s
immunotherapeutic products; for the treatment for pathologies relating to human papilloma virus
(HPV) infection that can lead to cervical cancer (TG4001), and for the treatment for non-small cell lung cancer (NSCLC) (
TG4010)"


Also an AIDs vaccine in development and has been approached by a few companies for licensing opportunities

"Given the current buoyancy of the life sciences sector, the Board has been approached by third parties to explore opportunities for collaboration with the Company on developing its current patent portfolio. "


One to watch